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Abstract
Background: Symptoms of theophylline toxicity and factors that augment the risk of developing it are well
documented in the literature. However these appear to be poorly considered in clinical practice. This case
underlines the challenges in recognising and managing theophylline toxicity; moreover the requirement for
improved application of knowledge of its pharmacokinetics to our practice.
Case Presentation: In this case we observe how theophylline toxicity can be overlooked due to the presence of
non-specific symptoms and lack of a structured system to mitigate error in detection, in both hospital medicine
and general practice. Here, the initial theophylline concentration measurement was documented as 59.3 mg/l in a
patient taking the medication long-term, with the previous concentration being recorded one year prior. Management
consisted of suspension of theophylline along with best supportive care, however in the process other conditions were
exacerbated and the patient ultimately died in hospital. Congestive cardiac failure, congestive liver disease and
polypharmacy were factors isolated from this case that expedited the patients’ development of theophylline
toxicity. This was perpetuated by delay in diagnosis due to presentation with generalised symptoms including
tachycardia, vomiting and neurological symptoms.
Conclusions: Findings from this case necessitate a requirement for more stringent monitoring of theophylline
when taken chronically in those who demonstrate risk factors for toxicity. This would aim to prevent
accumulation of the drug, toxicity onset and subsequent acute presentation to hospital. Intervention, through
charcoal haemoperfusion may provide a means of enhanced recovery to reduce sequelae of toxicity.
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Background
Theophylline is a member of the methylxanthine class of
medications and is typically used in the management of
patients with airway disorders such as Chronic Obstruct-
ive Pulmonary Disease (COPD) and asthma. This is due
to its relaxing effect on smooth muscle within the bronchi
and pulmonary vasculature, as well as stimulating central
respiratory drive [1]. Theophylline is used in the manage-
ment of reversible airways obstruction or exacerbations of
COPD [2], it is typically an adjunct to other, more com-
monly prescribed medications, such as beta-2 agonists
and steroids. The dose is typically started at 225 mg BD
and then increased to 450 mg BD after one week. Classic-
ally, theophylline is not prescribed as a first-line medica-
tion due to its narrow therapeutic index, the British
National Formulary (BNF) suggest target plasma concen-
trations of 10–20 mg/l [2].
This case outlines an example of the severity of adverse
effects demonstrated by theophylline; furthermore we
explore the pitfalls in recognising theophylline toxicity,
particularly when taking the medication chronically. Many
of the typical symptoms of theophylline toxicity are non-
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specific, which further perpetuates the challenges of rec-
ognition in a long-term user. These include nausea, vomit-
ing, fatigue, tachycardia and central nervous system (CNS)
effects such as dizziness and seizures [3]. When given in
the acute setting, more precautions are taken to monitor
serum concentrations. However it appears we are less
stringent on monitoring when the medication is taken
chronically, as exemplified in this case. The BNF suggests
monitoring every 6–12 months for those patients on a
stable dose [4]. However significant individual variations
in hepatic metabolism of the drug also contribute to a dif-
ficulty in maintaining a therapeutic concentration.
The aim of this report is to provide a case-based ex-
ample to advocate more stringent theophylline concen-
tration monitoring, particularly in patients considered
high risk for toxicity. The intention is to help prevent
toxicity occurring in patients taking this medication
long-term.
Case Presentation
Mrs. E was a 57-year-old lady with a 12-year history of
COPD, with an FEV1 of 30 %. Furthermore, she had a
past medical history of carcinoma of the breast, type 2
diabetes mellitus and left ventricular failure (LVF), which
was diagnosed on an echocardiogram (ECHO) in July
2014. Despite a diagnosis of COPD she continued to
smoke 20–30 cigarettes/day.
She was prescribed a number of medications to help
manage her airways disease including tiotropium, sere-
tide 500, salbutamol, prednisolone and most recently
oral theophyline (450 mg twice daily), which was started
in April 2013 as an adjunct to her current medications.
She was admitted in June 2015 following a fall with not-
able decreased sensation bilaterally in her lower limbs and
a tachycardia of 133 beats per minute. Spinal cord com-
pression was an initial concern, however this was excluded
with a magnetic resonance imaging (MRI) spine. There
was no change to her theophylline prescription on admis-
sion to hospital and no new medication was prescribed
that would affect theophylline metabolism.
Over several days additional symptoms were noted,
including worsening nausea, blurred vision, increasing
fatigue (with stable blood sugars) and worsening speech
with slurring of words. Development of vomiting resulted
in a decision to measure her theophylline concentration
and perform a CT head, as no obvious cause for her symp-
toms had been elicited. The CT head was reported as clear
of any ischaemia, haemorrhage or space-occupying lesion.
The trough theophylline concentration was 59.3 mg/l.
The last result obtained in July 2014 during an admission
for influenza related infective exacerbation of COPD was
reported as 20.2 mg/l, marginally above the 10-20 mg/l
recommended reference range. The concentration was
then not re-checked either in primary care or in hospital;
it therefore became apparent this was a case of chronic
theophylline toxicity.
Management
The medical team at The National Poisons Information
Service was contacted for advice on management of this
patient. The rationale being abnormally high theophylline
concentration, furthermore this was a case of chronic, ra-
ther than acute toxicity, for which we felt specialist input
was required.
The patient was monitored for significant effects of
toxicity; these include seizures (reported at trough con-
centrations of 50 mg/l [5]), reduced conscious level and
tachyarrhythmias. Although Mrs. E suffered a persistent
tachycardia, her heart rate remained in sinus rhythm.
Cardiac monitoring was started. She was managed con-
servatively by stopping the theophylline and monitoring
symptoms. Due to vomiting, oral activated charcoal was
excluded and although charcoal haemoperfusion was
discussed, it was not accessible at the RUH and as Mrs.
E was haemodynamically stable and not acidotic, it was
deemed not to be essential. This point will be discussed
further in the conclusion.
Mrs. E developed electrolyte imbalances not long after
the vomiting started, suffering hypokalaemia (3.2 mmol/
l), hypomagnaesemia (0.56 mmol/l) and hypocalcaemia
(1.96 mmol/l). This was postulated to be secondary to
both vomiting and theophylline accumulation. This sub-
sequently resulted in a pseudo-obstruction, diagnosed
on abdominal x-ray. A nasogastric tube was placed and
she was supplemented with appropriate electrolytes via
intravenous infusion. An arterial blood gas demonstrated
a pH 7.398 (7.34-7.44), pO2 (kPa) 9.24 (11–14), pCO2
(kPa) 6.36 (4.7-6.0), HCO3
− (mEq/l) 21.7 (22–26), lactate
(mmol/l) 1.5 (0.4-2.2). As no signs of acidosis were
present and bicarbonate was at the low end of the nor-
mal range, we decided not to prescribe bicarbonate for
this patient.
After stopping her theophylline and without any active
intervention her serum concentration fell gradually
(Table 1). By the time her theophylline concentration
was within therapeutic range, her electrolytes had been
corrected and her pseudo-obstruction had resolved.
However, she developed signs of fluid overload, her
heart rate also remained in persistent sinus tachycardia.
Notably, findings of Congestive Cardiac Failure (CCF)
were demonstrated on a previous echocardiogram and
were substantiated by results of her computed tomog-
raphy (CT) abdomen/pelvis and ultrasound sonography
scan (USS) liver during her current admission; these
both showed abnormal appearances of the liver consist-
ent with cardiac dysfunction. It therefore appeared she
had developed acute CCF. Ultimately, this resulted in
challenging fluid balance management with serial chest
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x-rays demonstrating worsening bilateral effusions and
renal function continuing to decline until the death of
the patient.
Discussion
There are a number of key learning points to draw from
this case, pertaining to multiple areas of clinical practice.
In retrospect, it remains difficult to understand exactly
to what extent theophylline toxicity contributed to the
death of this patient with multiple co morbidities. How-
ever, what is clear from the literature and from this case
is that toxic theophylline concentrations can result in
significant morbidity with potentially fatal outcomes [6].
As a medication with a narrow therapeutic index and an
inexorable correlation between plasma concentration and
therapeutic/toxic effects, there should be an impetus on
close monitoring of serum concentration. Theophylline is
rapidly and completely absorbed after oral administration
and freely distributes throughout fat-free tissues. The drug
is primarily metabolised by the cytochrome P450 liver en-
zyme, CYP1A2, and also eliminated via the hepatic route,
with a half life of 9 h [7, 8]. There are a number of medica-
tions and conditions that can impact on this, rendering
theophylline a difficult drug to manage. One such condi-
tion is CCF with hepatic congestion, which has been dem-
onstrated to reduce the clearance by 50 % and double the
half life, thereby reducing drug elimination and increasing
concentrations [5, 9, 10]. Other recognised factors which
can reduce theophylline clearance include increased age
and liver enzyme inhibiting medications [11, 12]. A key
point that pertains to this case is that smoking is an in-
ducer of CYP1A2. We recognise that Mrs. E continued to
smoke until her final hospital admission, which theoretic-
ally would confer an increased elimination of theophylline
and act as protective mechanism against the development
of toxicity. To our knowledge she was receiving no medi-
cations that are inhibitors of this enzyme. However it is
critical to recognise these (Table 2.) as well as identifying
recent smoking cessation; as these could both significantly
impact on theophylline concentrations [13].
Indeed, we should approach treating patients with theo-
phylline, who have underlying CCF, with increased cau-
tion. With data demonstrating that elimination time of
the drug can be doubled [9, 10] with this condition, there
should be a greater onus on primary care physicians, as
well as hospital clinicians to monitor the serum concen-
tration to avoid chronic intoxication. It is sub-standard
practice to neglect to monitor theophylline concentrations
for over a year in a patient with established CCF, particu-
larly when they have had a previously high reading [14].
The BNF suggests that serum concentrations should be
measured every 6–12 months in patients with a stable
dose after 5 days [3]. However it would be reasonable to
suggest that those patients who have risk factors for re-
duced elimination or metabolism of the drug, such as
CCF or liver disease, are monitored at least every 6 months
to avoid the manifestation of significant intoxication and
avoid acute presentation.
When discussing with Mrs. E the reasons behind her
admission, it was interesting to hear that neither she,
nor her full-time carer, knew the name theophylline or
its indication. In cases of polypharmacy like this, it can
be challenging for patients to remember all medications,
their indication and associated adverse effects. This fur-
ther substantiates the argument for responsibility within
healthcare professionals to provide close monitoring and
support for these vulnerable patients.
Indeed there were shortcomings in patient manage-
ment in this case, however it is recognising intoxication
that poses one of the key challenges. This difficulty can
be attributed to the generalised symptoms displayed by
the patient. Neurological symptoms, fatigue, vomiting,
blurred vision; these are all symptoms that could be a
manifestation of multiple other disorders, especially in a
patient with multiple co-morbidities. Other reports have
described concomitant findings, outlining the challenges
of diagnosing theophylline toxicity in hospital due to the
broad array of symptoms at presentation [4]. We postulate
that better education around toxicology and an increased
Table 1 Theophylline measurements post stopping of the
medication








Serial theophylline readings recorded after stopping the medication. Initial
reading was a trough measurement post stopping the medication. Theophylline
reference range 10-20 mg/L









List outlining some commonly prescribed medications that are recognised to
inhibit CYP1A2
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awareness of chronic theophylline toxicity, as well as
serum concentration screening for all patients who
come through the emergency department taking this
medication, may help improve outcomes within the
hospital setting.
With regards to intervention, one study demonstrated
that in cases of severe theophylline toxicity (trough con-
centration >48 mg/l) there was a significant reduction in
morbidity and mortality to those patients who underwent
charcoal haemoperfusion [15]. This increases theophylline
clearance from the normal endogenous value of 50 ml/kg/
h up to 157 ml/kg/h [16]. In future cases, it would be in-
teresting to observe whether charcoal haemoperfusion
would enhance recovery from theophylline toxicity and
improve patient outcomes as the literature tenuously sug-
gests [15]? At what serum concentration would you ex-
pect to see a consistently significant benefit from this
therapy? Further research is required into charcoal hae-
moperfusion as well as incidence of theophylline toxicity
before this intervention can become more widely available
across hospitals.
Conclusions
Findings from this case necessitate a requirement for
more stringent monitoring of theophylline when taken
chronically in those who demonstrate risk factors for
toxicity. This would aim to prevent accumulation of the
drug, toxicity onset and subsequent acute presentation
to hospital. Intervention, through charcoal haemoperfu-
sion may provide a means of enhanced recovery to re-
duce sequelae of toxicity.
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